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Background: This randomized controlled trial (RCT) investigated the effectiveness of a combined treatment for co-
morbid Posttraumatic Stress Disorder (PTSD) and severe Substance Use Disorder (SUD).
Methods: Structured Writing Therapy for PTSD (SWT), an evidence-based traumafocused intervention, was added
on to Treatment As Usual (TAU), consisting of an intensive cognitive behavioral inpatient or day group treatment
for SUD. The outcomes of the combined treatment (TAU + SWT) were compared to TAU alone in a sample of 34
patients.
Results: Results showed a general reduction of SUD symptoms for both TAU + SWT and TAU. Treatment
superiority of TAU + SWT was neither confirmed by interaction effects (time x condition) for SUD or PTSD
symptoms, nor by a group difference for SUD diagnostic status at post-treatment. However, planned contrasts
revealed that improvements for PTSD severity over time were only significant within the TAU + SWT group. In
addition, within the TAU + SWT group the remission of PTSD diagnoses after treatment was significant, which was
not the case for TAU. Finally, at post-treatment a trend was noticed for between group differences for the number
of PTSD diagnoses favoring TAU + SWT above TAU.
Conclusions: In sum, the current study provides preliminary evidence that adding a trauma-focused treatment on
to standard SUD treatment may be beneficial.
Keywords: Posttraumatic stress disorder, Substance use disorder, Comorbidity, Randomized controlled trial,
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Over the past decade, the detection and treatment of
posttraumatic stress disorder (PTSD) among substance
use disorder (SUD) patients have increasingly been stud-
ied [1-3]. This trend mirrors a need in clinical practice
as the number of SUD patients meeting diagnostic cri-
teria for PTSD is relatively large (20-30%) [2,3]. Import-
antly, there is evidence that this patient group suffers
from more severe complaints and more relapses in* Correspondence: debora.van.dam@jellinek.nl
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reproduction in any medium, provided the orsubstance use than SUD patients without comorbid
PTSD [4,5]. This suggests that the common treatment
approach, whereby SUD and PTSD are treated sequen-
tially and within different treatment centers, may not be
optimal [6-8].
Several theories have been developed to explain the
high comorbidity between PTSD and SUD. Most evi-
dence is available for the self-medication theory [9],
which suggests that substances are used to alleviate or
suppress PTSD symptoms. In line with this theory, re-
search investigating the chronology of PTSD and SUD
has shown that SUD is preceded by PTSD more often
than vice versa [10,11], that the exacerbation of PTSD
symptoms is the most important factor in predictingal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ments in PTSD symptoms are associated with subse-
quent improvements in substance dependence [13,14].
In addition, experimental research suggests that trauma-
related cues can trigger a craving response [15].
On the other hand, there are also theoretical and em-
pirical grounds to assume an inverse relationship. The
high risk hypothesis poses that SUD augments the risk
for traumatic experiences and thereby the chance for
developing PTSD [16]. In addition, SUD may interfere
with habituation to the trauma memory [11], and the
withdrawal of substances may evoke traumatic memories
and trigger PTSD symptoms as it resembles physical
experiences during trauma [11]. In line with these
hypotheses, there is some evidence to suggest that in
some cases SUD precedes PTSD in the development of
this comorbidity; in addition, the treatment of SUD
alone has been shown to lead to a reduction of PTSD
symptoms [17-20].
Taken the two perspectives together, a reciprocal rela-
tionship between both disorders appears to be the most
likely explanation for the high co-morbidity between
PTSD and SUD [1,11]. This hypothesis is also supported
by recent data indicating that the vast majority of pa-
tients first reported trauma, then substance use, which
again was followed by additional traumatic experiences,
and further substance use [21]. This chronology suggests
that patients’ substance use indeed increases after having
experienced trauma, and that high levels of substance
use may in turn increase the risk for other traumatic
events. A mutual relationship between PTSD and SUD
implies that PTSD symptoms may exacerbate in the first
period of abstinence, and that PTSD complaints may
improve when abstinence is maintained. Consequently,
it appears likely that a sequential treatment approach in-
creases the risk that patients drop out of SUD treatment
prematurely and therefore do not receive PTSD treat-
ment either. It is therefore plausible to assume that
patients will benefit more from combined treatment
interventions for PTSD and SUD.
Existing treatments for concurrent PTSD and SUD are
based on two different approaches. Some authors sug-
gest that PTSD among SUD patients should be treated
according to the guidelines for PTSD in general, which
recommend trauma focused-cognitive behavioral treat-
ment (TF-CBT) and EMDR [22]. An important element
of TF-CBT is imaginal exposure. Patients are asked to
revisit their traumatic event in their imagination and
describe it in great detail [23]. In EMDR, the client is
instructed to focus on the traumatic memory and simul-
taneously perform rhythmic eye movements [24].
A contrasting point of view is that trauma-focused
interventions may be too invasive for patients with
concurrent PTSD and SUD, and that these interventionsput patients at risk for relapse, treatment dropout and
other adverse events [25,26]. Based on this idea, non-
trauma-focused interventions have been developed that
focus on the present or past aspects of the patient’s life
other than the trauma, and that do not require patients
to revisit or reprocess the trauma [e.g. 25]. The aim of
these treatments is to provide patients with coping skills
to manage their trauma symptoms and to improve func-
tioning. The majority of treatments developed for con-
current PTSD and SUD to date are non-trauma-focused
[7,27-29]. Although some programs include in vivo ex-
posure [29] or sharing traumatic experiences within the
group [28], they are best characterized as non-trauma-
focused treatments as they do not comprise exposure to
the trauma memory as a main ingredient. Existing
integrated treatments using a non-trauma-focused ap-
proach appear to be successful in reducing PTSD and
SUD symptoms, but their results are generally not
superior to active control conditions, such as regular
SUD treatment [1,30,31]. However, integrated cognitive
behavioral therapy, a non-trauma-focused therapy based
on a cognitive restructuring approach, appears to be a
positive exception to this rule [21].
Recent evidence suggests that patients with concurrent
PTSD and SUD may benefit from trauma-focused inter-
ventions, and that these interventions are more effective
in reducing symptoms of PTSD than treatment-as-usual
[1,32,33]. Importantly, it appears that exposure-based in-
terventions are not necessarily associated with an in-
crease in attrition or relapse to drugs or alcohol [35].
Until now, trauma-focused interventions have not been
studied within severe SUD patients allocated to intensive
SUD treatment. Attention for PTSD symptoms appears
especially important for this patient group as untreated
PTSD symptoms can be expected to be related to a
number of clinical complications. Earlier research has
shown that PTSD symptoms in SUD patients are associ-
ated with increased relapse in substance use [13,35,36],
and with more problems in mental health, physical
health, and social relationships [37]. To our knowledge,
this randomized controlled trial (RCT) is the first study
bridging this gap.
An evidence-based trauma-focused intervention for
PTSD was added on to a regular intensive cognitive
behavioral SUD program for severe SUD patients, which
was the treatment-as-usual (TAU) for this sample [38].
The study aimed to investigate the effectiveness of
adding PTSD treatment to the intensive SUD treatment
program compared to TAU, i.e. the intensive SUD treat-
ment program only. The trauma-focused intervention
was Structured Writing Therapy (SWT) for PTSD [39].
SWT uses specific writing assignments to reprocess
painful trauma memories, and it encourages cognitive
reappraisal of trauma-related thoughts and social sharing
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port the effectiveness of SWT in the treatment of PTSD
[39-41]. In addition, SWT has been shown to reduce
levels of intrusions and avoidance, depression, anxiety
and somatization [41].
The current study originated from an RCT investigat-
ing the effectiveness of an integrated outpatient treat-
ment for concurrent PTSD and SUD (Van Dam, Vedel,
Ehring, Emmelkamp: Integrated trauma-focused treat-
ment for concurrent posttraumatic stress disorder and
substance use disorder: a randomized controlled trial,
submitted). In comparison to the earlier study, the
current investigation focused on patients with more se-
vere SUD symptoms who were attending inpatient or
day treatment. Furthermore, in contrast to the earlier
study among outpatients SWT was not integrated into
the SUD intervention, but added on to TAU. The pa-
tients randomized to the experimental condition (TAU +
SWT) received 10 individual sessions of SWT in
addition to the regular SUD program. An add-on ap-
proach seemed more appropriate for this study as SWT
is provided as an individual therapy. By adding SWT on
to the regular SUD program, all patients received the
same group intervention for SUD. Therefore, they all
benefited equally from group dynamics, and they all re-
ceived the same dose of SUD treatment whether they
were allocated to TAU or TAU + SWT.
The aim of this RCT was to investigate the effective-
ness of a combined treatment for comorbid PTSD and
severe SUD. Three hypotheses were tested. The first hy-
pothesis was based on the theory that PTSD and SUD
are reciprocally related. In line with this assumption, we
expected that both TAU and TAU + SWT would be ef-
fective in decreasing symptoms of SUD and PTSD. Sec-
ondly, we expected that patients receiving TAU + SWT
would achieve significantly higher improvements on
PTSD symptoms than patients in the TAU condition.
Thirdly, following from the self-medication hypothesis
we hypothesized that TAU + SWT would be more effect-
ive in reducing symptoms of SUD than TAU alone.
Method
Participants
Figure 1 summarizes the flow of participants through
the study. A consecutive sample of 34 patients was
recruited from the Jellinek Substance Abuse Treatment
Center in Amsterdam, The Netherlands. All patients
were allocated to intensive inpatient or day group treat-
ment for SUD. Allocation for treatment followed the prin-
ciples of stepped care. Therefore, all patients included in
the current study suffered from severe substance abuse,
and had already been allocated to two or more SUD
therapies in the past five years. Three patients dropping
out the earlier study investigating integrated outpatienttreatment for concurrent PTSD and SUD (Van Dam,
Vedel, Ehring, Emmelkamp: Integrated trauma-focused
treatment for concurrent posttraumatic stress disorder
and substance use disorder: a randomized controlled trial,
submitted) were also included into the current study.
Recruitment and eligibility criteria were parallel to this
earlier study. Patients were recruited between July 2008
and July 2011. Inclusion criteria were: (1) a diagnosis of
substance abuse or substance dependence according to
DSM-IV, (2) a diagnosis of full-blown or partial PTSD
[42] according to DSM-IV (partial PTSD was defined as
meeting symptom criteria for the reexperiencing cluster
and for either the avoidance/numbing cluster or the
hyperarousal cluster), (3) being allocated to intensive
group treatment either as day treatment or as in-patient,
(4) being 18 years or older, and (5) sufficient under-
standing of the Dutch or English language. Exclusion
criteria were (1) a diagnosis of Borderline Personality
Disorder, (2) other severe (psychiatric) problems that
required immediate clinical care (e.g., psychotic symp-
toms, manic episode, current suicidal ideation, severe
domestic violence), (3) severe cognitive disorders, or
(4) receiving concurrent psychotherapy for any kind of
psychological disorder. Patients receiving medication for
psychological complaints (e.g., antidepressant medication)
were included in the study if they remained on a stable
dose during the course of the study. This was the case for
six patients (18%). At 3 month follow-up, patients were
asked whether they had been any change in medication
prescription during the follow-up interval. One patient
(3%) reported a change in medication treatment between
post-treatment and follow-up, and two patients (6%)
reported to have started new medication treatment within
a month after treatment. No group differences were found
between the CBT/SUD + SWT and CBT/SUD condition
for the number of patients using medication during treat-
ment, or medication changes after treatment (Fisher’s
exact test; p’s > .245).
Patients in both conditions were considered dropouts
if they ended TAU for SUD prematurely. Patients in the
TAU + SWT group were additionally labeled as dropout
if they attended less than 75% of the SWT treatment
sessions (≤ 7). Dropout patterns for TAU + SWT (N = 19)
revealed that ten patients completed treatment (53%). The
other nine patients ended treatment before the fifth SWT
session (47%). Three of them dropped out of treatment
even before SWT started (33%). In this study, non-
response was not equal to treatment dropout, as all pa-
tients could participate in study measurements whether
they completed treatment or not.
Tables 1 and 2 summarize sample characteristics and
between group analyses. The overall sample consisted
of 23 males and 11 females, with a mean age of 42.3
(SD = 9.0). No significant differences between treatment






36 t1 (pre-treatment) 
6 declined (did not 
want to participate)
36 randomly allocated
16 completed t2 (mid-treatment)
14 completed t3 (post-treatment)
14 completed t4 (3 mo follow up)
19 in ITT analyses 
11 completed t2 (mid-treatment)
13 completed t3 (post-treatment)
13 completed t4 (3 mo follow up)
15 in ITT analyses 
34 received ≥ 1 session
2 patients referred to TAU withdrew 
from study after randomization.
466 ineligible
205 no (subthreshold) PTSD    
141 allocated to outpatient 
treatment    
44 severe (psychiatric) problems 
23 concurrent psychotherapy
23 Borderline Personality Disorder                 




Figure 1 CONSORT flowchart of the recruitment and retention of participants. t1 = baseline; ITT = Intent-to-treat.
van Dam et al. BMC Psychiatry 2013, 13:172 Page 4 of 13
http://www.biomedcentral.com/1471-244X/13/172conditions were found for sample characteristics, or drop-
out rates χ2’s (1, N = 34)≤ 3.03, p’s ≥ .22. In addition, no
group differences were revealed for baseline symptom
severities t’s (32) ≤ 0.617, p’s ≥ .54, or for diagnostic status,
Fisher’s exact p’s ≥ .08.
Treatments
Treatment as usual (TAU) consisted of a regular intensive
treatment program for SUD based on the principles of
cognitive behavioral therapy (CBT) [38]. The treatment
was delivered in a group format, and included coping skill
training for alcohol and/or drug abuse, an evidence-based
treatment for SUD [38]. Coping skill training for SUD
teaches patients to recognize high risk situations preced-
ing substance use, and offers strategies to deal with crav-
ing and relapse. Training tools are modeling, behavioral
practice and homework assignments [43]. Coping skills
training for SUD was offered twice a week for the first
six weeks (2 h group sessions). After that, weekly
sessions were provided for a period of 8 weeks.Furthermore, TAU incorporated social skills training, relax-
ation training, psycho-education, motivational interviewing
sessions, basic CBT-training, relapse prevention sessions
and emotion-regulation training. In addition to attending
the group training program, patients had weekly sessions
with an individual therapist. No interventions related to
PTSD symptoms were carried out during these individual
treatment sessions. The duration of the intensive part of
the treatment program varied from 6 to 12 weeks. On
average, patients attended the program four days a week.
Dependent on the individual needs of each patient, TAU
could be followed on an inpatient or an outpatient (day
treatment) basis. All patients followed a detoxification
program before starting the treatment program.
TAU + SWT existed of the same treatment program as
described above, except for ten individual sessions of
SWT that were added on to the program. SWT started
after patients had been abstinent for 4 to 6 weeks. The
treatment was drawn from a former protocol [44]. Ther-
apy sessions were offered weekly and lasted 45–60 min.
Table 1 Sample characteristics: demographic variables
Demographics Total (n = 34) TAU + SWT (n = 19) TAU (n = 15) Between group analyses
Mean age (SD) 42.3 (9.0) 42.6 (8.4) 41.9 (10.0) t (33) = 0.21, p = .84
Gender, n (%) χ2 (1, N = 34) = 0.012, p = .92
Male 23 (67.6) 13 (68.4) 10 (66.7)
Female 11 (32.4) 6 (31.6) 5 (33.3)
Ethnicity, n (%) χ2 (4, N = 34) = 2.962, p = .56
Dutch 23 (67.6) 13 (68.4) 10 (66.7)
European (other) 2 (5.9) 1 (5.3) 1 (6.7)
Arabic/ Moroccan/ Turkish 4 (11.8) 1 (5.3) 3 (20.0)
Black/ Surinamese/ Caribbean 4 (11.8) 3 (15.8) 1 (6.7)
Other 1 (2.9) 1 (5.3) 0 (0)
Education (certificate), n (%) χ2 (3, N = 34) = 0.404, p = .94
No education, primary school 11 (32.4) 6 (31.6) 5 (33.3)
Secondary school, lower level 8 (23.5) 4 (21.1) 4 (26.7)
Secondary school, higher level 9 (26.5) 5 (26.3) 4 (26.7)
Postsecondary 6 (17.6) 4 (21.1) 2 (13.3)
Relationship status, n (%) χ2 (2, N = 34) = 2.859, p = .24
Single 31 (91.2) 17 (89.5) 14 (93.3)
Partner 2 (5.9) 2 (10.5) 0 (0)
Missing 1 (2.9) 0 (0) 1 (6.7)
Source of income, n (%) χ2 (2, N = 34) = 3.026, p = .22
No work 22 (64.7) 10 (52.6) 12 (80.0)
Work 11 (32.4) 8 (42.1) 3 (20.0)
Missing 1 (2.9) 1 (5.3) 0 (0)
Dropouts, n (%)
SUD treatment & SWT 13 (38.2) 9 (47.4) 4 (26.7) χ2 (1, N = 34) = 1.521, p = .30
SUD treatment 12 (35.3) 8 (42.1) 4 (26.7) χ2 (1, N = 34) = 0.875, p = .48
Baseline Measures
Mean PDS (SD) 29.5 (10.0) 30.4 (9.7) 28.3 (10.7) t (33) = 0.62, p = .54
Mean TLFB (SD) 20.0 (27.2) 19.9 (29.3) 20.1 (25.4) t (33) = 0.19, p = .99
Note: TAU Treatment As Usual, SWT Structured Writing Treatment.
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confrontation, cognitive reappraisal and sharing/farewell.
The self-confrontation phase comprised trauma-focused
exposure, and guided patients to write in detail about
the most traumatic event(s) they had experienced. The
writing had to be in the first person and in the present
tense, addressing sensory experiences, painful facts,
thoughts and emotions experienced during the trauma.
The phase of cognitive reappraisal focused on changing
dysfunctional appraisals related to the traumatic event
and its consequences. For this purpose, patients were
asked to write a letter of advice to an (imaginary) friend
or loved one, imagining that they had experienced the
same event. Patients were asked to give advice to this
person on how to handle thoughts, emotions and conse-
quences related to the trauma. In a second step, thepatient was instructed to write a similar letter to him- or
herself. The final phase consisted of a ‘sharing and
farewell ritual’ that was aimed at finding closure of the
traumatic event(s). In this final letter, the patient
reflected on the trauma, its impact on his/her life, and
his/her resolutions for dealing with the trauma in the fu-
ture. During the whole treatment, writing assignments
were introduced and discussed during the treatment
sessions. TAU + SWT also incorporated two flexible
sessions. Patients and therapists could decide what of
the former SWT assignments they wanted to give extra
attention. If necessary, it was possible to use the flexible
sessions in advance to prolong the self-confrontation or
the cognitive reappraisal phase.
In order to prepare patients with concurrent PTSD
and SUD for possible difficulties during detoxification
Table 2 Sample characteristics: diagnostic status (current)
Diagnostic status Total (n = 34) TAU + SWT (n = 19) TAU (n = 15) Between group analyses (Fisher’s exact)
PTSD diagnosis (full-blown), n (%) 21 (61.8) 9 (47.4) 12 (80.0) p = .08
Primary SUD diagnosis, n (%)
Alcohol, not in remission 16 (44.1) 11 (57.9) 5 (33.3) p = .19
Drugs, not in remission 15 (44.1) 8 (42.1) 7 (46.7)
Cannabis 4 (11.8) 1 (5.3) 3 (20.0) p = .30
Cocaine 10 (29.4) 6 (31.6) 4 (26.7) p = 1.0
Other 1 (2.9) 1 (5.3) 0 (0) p = 1.0
Substance Dependence 30 (88.2) 18 (94.7) 12 (80.0) p = .30
Substance Abuse 1 (2.9) 1 (5.3) 0 (0) p = 1.0
Other axis-I diagnoses, n (%)
Depressive disorder 11 (32.4) 4 (21.1) 7 (46.7) p = .15
Panic disorder 3 (8.8) 1 (5.3) 2 (13.3) p = .57
Panic disorder with agoraphobia 2 (5.8) 0 (0) 2 (13.3) p = .19
Social Phobia 4 (11.8) 2 (10.5) 2 (13.3) p = 1.0
Specific phobia 2 (5.8) 1 (5.3) 1 (6.7) p = 1.0
Obsessive compulsive disorder 0 (0) 0 (0) 0 (0) -
General anxiety disorder 1 (2.9) 0 (0) 1 (6.7) p = .44
Eating disorder 0 (0) 0 (0) 0 (0) -
van Dam et al. BMC Psychiatry 2013, 13:172 Page 6 of 13
http://www.biomedcentral.com/1471-244X/13/172and SUD treatment, psycho-education about the vicious
circle of PTSD and SUD was provided in the first treat-
ment session [6]. For ethical reasons, psycho-education
was not only provided in the TAU + SWT condition, but
also in the TAU condition. Patients in the TAU + SWT
group received psycho-education from their SWT
therapist. In the TAU condition, psycho-education was
provided by the individual TAU therapist.
Therapists
All SWT therapists were regular therapist of the Jellinek
with a master’s degree in clinical psychology and add-
itional formal training in cognitive behavioral therapy.
Therapist treatment adherence was monitored in weekly
supervision sessions by the last author.
Measures
The outcome measures for PTSD and SUD were change
in the severity of PTSD symptoms and change in sub-
stance use, respectively. Further outcome measures were
PTSD and SUD diagnostic status. The Posttraumatic
Diagnostic Scale (PDS) [45] was used to assess PTSD
symptom severity. The PDS consists of 17 items corre-
sponding to the DSM-IV PTSD, that are rated on a 4-
point Likert-scale (0 = not at all or only one time; 3 = five
or more times a week/almost always), and 9 items
assessing impairment in different life areas. PTSD symp-
tom severity scores are obtained by summing the 17
symptom items, with higher scores indicating greater
symptomatology [45]. The PDS has shown to performwell within an SUD population, revealing excellent in-
ternal consistency, good test –re-test reliability, and
good convergent validity with PTSD diagnosis [46]. Also,
high sensitivities, and moderate specificities were found
for the PDS within this population [3,46]. By means of
the Timeline Follow Back (TLFB) [47], retrospective esti-
mates of daily use of alcohol and drugs were obtained for
a time frame of 90 days. Its psychometric characteristics
for alcohol use have been extensively evaluated [48,49]. In
our study, alcohol consumption was converted to standard
drinks, and drug use was converted to grams.
DSM-IV axis I disorders, including SUD and PTSD,
were assessed with the Structured Clinical Interview for
DSM-IV Axis I Disorders (SCID-I) [50,51]. The SCID-I
has shown a fair interrater agreement for the SUD mod-
ule (kappa = 0.65), and an excellent interrater agreement
for the PTSD module (kappa = 0.77) [52]. To screen for
(partial) PTSD, the Jellinek-PTSD (J-PTSD) screening
questionnaire was used [53]. The J-PTSD was specific-
ally developed to screen for PTSD in SUD patients. The
sensitivity (.87), specificity (.75), and overall efficiency
(.77) are high using a cutoff score of 2 [53]. The McLean
Screening Instrument for Borderline Personality Disorder
(MSI-BPD) [54] was used to screen for Borderline
Personality Disorder (BPD). The MSI-BPD has shown a
good sensitivity (.81) and specificity (.85) for a cutoff
score of 7 [54]. Patients with a score of ≥ 7 were invited
for further assessment. Borderline Personality Disorder
was assessed with the Structured Clinical Interview for
DSM-IV Axis II Disorders (SCID-II) [55]. The SCID-II
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module (kappa = 0.91) [52].
Procedures
All patients attending a regular intake at the Jellinek
were screened with the Jellinek-PTSD screening ques-
tionnaire for PTSD. If the screener was positive, patients
were invited for further assessment in order to deter-
mine diagnostic status. If a formal diagnosis for (partial)
PTSD was obtained, eligible patients received written
information about the study and gave written informed
consent. Patients willing to participate were invited again
for the pre-treatment assessment (t1). After pre-treatment
assessment, patients were randomly assigned to either
TAU + SWT or TAU by asking them to draw one out of
two closed envelopes. Each patient was approached for an
additional three assessments during the study: mid-
treatment (t2) (after the fifth session), post-treatment (t3),
and 3 months post-treatment (t4). Patients were invited to
the Jellinek treatment center for all assessments, except
for the shorter 3-month follow-up, which was adminis-
tered via telephone. If a patient was unable to come to the
Jellinek for a face-to-face assessment, the mid-treatment
or post-treatment assessments were also administered by
telephone (n = 7 at post-treatment). There was no financial
compensation for research and treatment participation.
The study was approved by the ethics committee of
the University of Amsterdam (Faculty of Social and Be-
havioral Sciences; reference number 2008-KP-342), and
submitted to the Clinical Trials Register, ClinicalTrials.
gov (Trial # NCT00763542).
Statistical methods
All analyses were performed using the IBM Statistical
Package for Social Science (SPSS), version 19.0 for
Windows. T tests and χ2 tests were used to compare
both treatment conditions on sample characteristics and
dropout rates. Treatment effects were investigated with
intent to treat (ITT) analyses. Patients were categorized
as ITT if they attended at least one therapy session.
Overall missing data patterns showed very low percentages
of item non-response (< 2%), except for one secondary out-
come measure concerning craving (5% item non-response).
This justified the use of response function imputation [56].
Figure 1 shows that unit non-response was lower than 21%
over all measurements.
Missing data by unit non-response was handled by
Multiple Imputation (MI) (m = 5). Whole scales were
imputed using the complete datafile (k = 91) [57]. All
analyses were performed on average values derived from
the imputed dataset. For the dependent variables PDS
total score and TLFB (days of abstinence) a General
Linear Model (GLM) repeated measures was performed.
Planned repeated contrasts for time were performedfor each condition separately (at mid-treatment, post-
treatment, and at 3 month follow up). Rank-transformation
was performed additionally if variables were not normally
distributed [58].
Non-parametric tests were used to examine differences
for diagnostic status (Fisher’s exact test, and McNemars χ2)
from pre- to post-treatment and follow-up. Effect sizes
were calculated for all primary outcome measures.
Results
Treatment effects
Descriptive data for the primary outcome measures are
displayed in Tables 3 and 4. All values are estimated
values based on pooled outcomes on the imputed
dataset. The outcome measures for PTSD were PTSD
symptom severity (PDS) and PTSD diagnostic status
(SCID diagnosis). The outcome measures for SUD were
the number of abstinent days (TLFB) and SUD diagnos-
tic status (SCID diagnosis).
PTSD symptom severity
GLM repeated measures analyses on the imputed
dataset revealed a main effect for time, F(3, 34) = 6.37,
p = .001, partial η2 = 0.166, and no main effect for condi-
tion F(1, 34) = 0.01, p = .921, partial η2 = 0. No significant
interaction effect was found between condition and
time F(3, 34) = 1.92, p = .132, partial η2 = 0.059.
Planned contrast analyses were performed for both
treatment groups to assess the decrease in symptoms from
pre- to mid-treatment, from mid- to post-treatment, and
from post-treatment to follow-up. For the TAU + SWT
group a significant decrease in PTSD severity was found
from mid-treatment to post-treatment F(1, 19) = 9.31,
p = .007, partial η2 = 0.341, but not from pre-treatment to
mid-treatment F(1, 19) = 0.67, p = .424, partial η2 = 0.036,
or from post-treatment to follow up F(1, 19) = 3.01,
p = .100, partial η2 = 0.143. For the TAU group no signifi-
cant decreases in PTSD symptom severity were found
between the measurement points F’s (1, 15) ≤ 0.924,
p’s ≥ .353, partial η2’s ≤ 0.62.
PTSD diagnostic status
For both conditions, differences for PTSD diagnostic
status were investigated with McNemar χ2. Overall, a
significant increase was found for the number of remit-
ted cases (partial and full-blown) in the TAU + SWT
condition, McNemars χ2 (1, N = 19) = 8.2, p = .004. More
specifically, there was a significant decrease for partial
PTSD McNemars χ2 (1, N = 19) =5.07, p = .024, but not
for full-blown PTSD, McNemars χ2 (1, N = 19) = 0.17,
p = .680. For TAU, no differences were found for PTSD
diagnoses, McNemars χ2 (1, N = 26) ≤ 1.00, p’s > .317.
To investigate differences for PTSD diagnoses between
TAU + SWT and TAU at post-treatment, a Fisher’s





TAU + SWT (A) (N = 19) TAU (B) (N = 15) GLM Partial η2 Contrast Partial η2 GLM Partial η2 GLM partial
bη2




2 mid-post 2 mid-post
3 post-fu 3 post-fu
PDS total:
M (SD)
30.4 (9.7) 28.2 (9.0) 17.6 (12.0) 23.5 (14.8) 28.3 (10.7) 26.5 (9.8) 24.3 (9.1) 21.7 (9.4) A + B
**
0.166 1 A ns B ns A 0.036
B 0.037
ns 0.000 ns 0.059
2 A * B ns A 0.341
B 0.040
3 A ns B ns A 0.143
B 0.062
McN χ2 OR 3 Fisher t 4 φ5
SCID (PTSD)
n (%)
PTSD 19 (100) - 9.8 (51.8) - 15 (100) - 13.2
(88.0)
- A* 0 - −0.390 - -
B 0Partial &
Full-blown




9 (47.4) - 7 (36.8) - 12 (80.0) - 10.8
(72.0)
- A 0.7 - −0.353 - -
B 0.8
Note. PTSD Posttraumatic Stress Disorder, TAU Treatment as usual, SWT Structured Writing Therapy, PDS Posttraumatic Diagnostic Scale, SCID Structured Clinical Interview of DSM IV, PTSD Posttraumatic stress disorder,
A = TAU + SWT. B = TAU. pre pre-treatment, mid mid-treatment, post post-treatment, Fu follow up. McN χ2 = McNemars χ2. OR odds ratio, Pl Con planned contrasts.
*p <0.05 **p < 0.001. t trend, ns not significant.
3OR = increase of cases/ decrease of cases.
4Overall Fisher’s excact test was calculated for PTSD diagnosis (p = 0.06).



















Table 4 Descriptive analyses for SUD for intent to treat sample (N = 34) (estimated values)
Variable (primary
outcome measures)
TAU + SWT (A) (N = 19) TAU (B) (N = 15) GLM Partial η2 Contrast Partial η2 GLM Partial η2 GLM partial η2




2 post-fu 2 post-fu
TLFB M (SD) Number of
abstinent days
19.9 (29.3) 76.8 (15.5) 61.0 (30.8) 20.1 (25.4) 66.0 (30.3) 58.6 (38.4) A + B ** 0.570 1 A * B * A 0.784
B 0.668
ns 0.011 ns 0.15
2 A * B ns A 0.292
B 0.052
McN χ2 OR 5 Fisher φ
SCID n (%) Primary SUD
diagnosis
- -
In remission 6 1 (5.3) 16.6 (87.4) - 3 (20.0) 10.2 (68.0) - A ** 15.6/0 ns −0.244 - -
B * 7
SCID n (%) 7 Total N
SUD diagnoses
- -
In remission 1 (5.3) 16.4 (86.3) - 3 (20.0) 9.2 (61.3) - A ** 15.4/0 ns −0.293 - -
B t 8 4.9
(Single SUD diagnosis,
not in remission)
9 (47.4) 2.6 (13.7) - 6 (40.0) 5.8 (68.7) - - - - - - -
(2 SUD diagnoses not in
remission)
6 (31.6) 0 (0) - 3 (20.0) 0 (0) - - - - - - -
(≥ 3 SUD diagnosesnot
in remission)
3 (15.8) 0 (0) - 3 (20.0) 0 (0) - - - - - - -
Note. PTSD Posttraumatic Stress Disorder, TAU Treatment as usual, SWT Structured Writing Therapy, PDS Posttraumatic Diagnostic Scale, SCID Structured Clinical Interview of DSM IV, PTSD Posttraumatic stress disorder,
A = TAU + SWT. B = TAU. pre pre-treatment, mid mid-treatment, post post-treatment, Fu follow up. McN χ2 = McNemars χ2. OR odds ratio, Pl Con = planned contrasts * p <0.05 **p < 0.001. t trend. ns not significant,
φ Phi (measure of effectsize).
5OR = increase of cases/ decrease of cases (Breslow & Day, 1980). OR was not calculated when the denominator equals zero.
6SUD has been diagnosed, however the diagnosis is partially or completely in remission during the last month.
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http://www.biomedcentral.com/1471-244X/13/172exact test [a] was carried out. Post-treatment results
indicated a trend for between-group differences in
PTSD diagnostic status (p = .06). After TAU + SWT
less patients were diagnosed with PTSD than after
TAU.
Abstinence
Overall abstinence from alcohol and drugs was calculated
from participants’ TLFB reports for a 90 day time window.
The GLM analysis showed a significant main effect for
time F(2, 34) = 42.38, p < .001, partial η2 = 0.570, indicating
an increase for the number of drug and alcohol free days
from pre-treatment to follow up. Neither a main effect for
condition F(2, 34) = 0.35, p = .557, partial η2 = 0.011,
nor an Time x Condition interaction effect were found,
F(2, 34) = 0.48, p = .620, partial η2 = 0.15. Outcomes
were similar after rank-transformation [59].
For each treatment condition, planned contrast ana-
lyses were performed to assess changes in abstinence
from pre- to post-treatment, and from post-treatment
to follow-up. For TAU + SWT, significant increases in
abstinence were found from pre-treatment to post-
treatment F(1, 19) = 65.21, p < .001, partial η2 = 0.784,
and significant decreases in abstinence from post-
treatment to follow-up F(1, 19) = 7.422, p = .014, partial
η2 = 0.292. The TAU group only revealed an increase for
abstinence from pre-treatment to post-treatment F(1, 15) =
28.139, p < .001, partial η2 = 0.668. No significant changes
for abstinence were found for TAU from post-treatment
to follow-up F(1, 15) = 0.767, p = .396, partial η2 = 0.052.
SUD diagnostic status
To compare SUD diagnostic status from pre- to post-
treatment, McNemar χ2 analyses were performed for
each treatment group. Outcomes for TAU + SWT all
showed significant decreases for SUD diagnostic status.
McNemars χ2’s (1, N = 19) ≥ 14.4, p’s < .001). For TAU,
the number of Primary SUD diagnoses decreased sig-
nificantly from pre- to post-treatment, McNemars χ2 (1,
N = 15) = 4.7, p = .03, and a trend was noticed for the
decrease of total number of SUD diagnoses, McNemars
χ2 (1, N = 15) = 3.4, p = .06.
Post-treatment differences for SUD diagnostic status
between TAU + SWT and TAU were investigated by
means of Fisher’s exact tests [b] , which revealed no
differences between both groups (p’s > .23).
Discussion and conclusions
The aim of this RCT was to investigate the effectiveness
of adding treatment for concurrent PTSD on to an in-
tensive SUD treatment program. It was expected that
the combination of these two evidence-based treatments
would lead to improved prognoses.According to the first hypothesis, a reduction of SUD
and PTSD symptoms was expected in both conditions.
This expectation was generally confirmed by findings for
SUD. Overall, there was a significant decrease of SUD
symptoms from pre-treatment to follow-up. Planned
contrasts showed an increase in abstinence for both
TAU and TAU + SWT during treatment, but also some
decrease of improvements from post-treatment to
follow-up for TAU + SWT. In addition, both groups
showed a significant remission for the primary SUD
diagnosis. Furthermore, a significant reduction for the
total number of SUD diagnoses was found in the TAU +
SWT group, and a trend was found for TAU. In sum,
both conditions were effective in reducing SUD, which
was to be expected as SUD was targeted in the same
way in both groups. Importantly, the current results also
show that it appears safe to provide trauma-focused
treatment for PTSD in combination with SUD treat-
ment, which is in contrast to frequent clinical belief.
Based on the idea that SUD and PTSD are mutually
maintained by a vicious cycle, it was expected that suc-
cessful SUD treatment should also reduce symptom
levels of PTSD. Hypothesis 1 therefore also predicted
that PTSD should significantly be reduced in both treat-
ment conditions. At the same time, Hypothesis 2 pre-
dicted that PTSD should improve more after combination
treatment compared to TAU. Analyses testing these two
hypotheses provided somewhat mixed results. Symptom
levels of PTSD significantly decreased over time in the
overall sample, which can be interpreted as support for
Hypothesis 1. In contrast to Hypothesis 2, no significant
interaction between time and condition emerged, i.e. we
did not find clear-cut evidence for a superiority of SWT+
TAU over TAU. However, there was indirect evidence
suggesting that the addition of SWT to TAU may be bene-
ficial. First, planned contrasts showed only a significant
reduction of PTSD symptoms during SWT for the TAU +
SWT group, but no significant reductions for PTSD dur-
ing or after TAU. This indicates that the overall decrease
of PTSD in both groups could mainly be attributed to the
results of the SWT+TAU condition. Furthermore, PTSD
diagnoses decreased in both conditions, but this reduction
was only significant in the TAU + SWT condition. Finally,
at post-treatment a trend was found for between-group
differences for PTSD diagnostic status, indicating that
fewer patients were diagnosed with PTSD (partial or full-
blown) after TAU+ SWT than after TAU.
Thirdly, we expected that TAU + SWT would be more
effective in reducing symptoms of SUD than TAU alone.
This prediction was based on the self-medication hy-
pothesis, which suggests that successful PTSD treatment
may lead to more sustainable abstinence as the need to
self-medicate is reduced. This hypothesis was not
supported by any type of analysis.
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http://www.biomedcentral.com/1471-244X/13/172In sum, both treatments were found to be equally ef-
fective in treating SUD. We found preliminary evidence
suggesting that SWT + TAU may be more effective in
treating PTSD symptoms than TAU, although this was
not supported by the crucial Time x Condition inter-
action on PTSD symptom severities, but only by a num-
ber of indirect findings. The fact that the interaction
effect was not significant may be due to different factors.
First, differences between both groups were difficult to
detect, due to the small sample size and therefore re-
duced power. Another possibility is that the dose of
SWT treatment was too low to realize significant im-
provements for PTSD symptoms. Interestingly, the re-
duction of diagnostic status in the combination
condition was only significant for the partial PTSD
group but not for patients with full-blown PTSD. This
could also be interpreted as support for the idea that
trauma survivors with SUD and high symptom levels of
PTSD may need a higher dose of treatment. In any case,
a replication of the findings in a larger sample is neces-
sary before any firm conclusions can be drawn.
In an earlier study, we evaluated integrated trauma-
focused SWT for PTSD and CBT for SUD within a larger
sample of outpatients (N= 96) (Van Dam, Vedel, Ehring,
Emmelkamp: Integrated trauma-focused treatment for
concurrent posttraumatic stress disorder and substance
use disorder: a randomized controlled trial, submitted).
These outcomes showed that PTSD and SUD symptoms
were treated effectively in both conditions. In addition,
completer analyses favored trauma-focused integrated
treatment above CBT for SUD in reducing PTSD symp-
tom severity. Apart from sample size, there were other
important differences in sample characteristics between
the present and the previous study. Most importantly, the
current patient sample was more severe. This was mir-
rored by the need for a more intensive treatment program
for SUD complaints, but also in less mean abstinent days
at baseline (20 versus 34) and slightly higher mean base-
line scores for PTSD (30 versus 27). Sample characteristics
for both studies showed that the current sample com-
prised relatively more men, more patients with a lower
education, more patients without a relationship, and more
patients without work. Although the present patient group
was more severe, overall dropout percentages were lower
(overall: 38%; TAU + SWT: 47%; TAU: 27%), compared to
the previous study (overall: 46%; TAU + SWT: 51%; TAU:
40%), but also compared to other findings in this area of
research [1]. Importantly, dropout percentages did not dif-
fer significantly between conditions, although a study
comprising a larger sample size and therefore higher stat-
istical power is necessary to provide conclusive evidence
on this issue. Although the dropout rates observed in the
current study are comparable to earlier research in this
field, they are nevertheless far from satisfactory. Futureresearch should aim at improving the acceptability of inte-
grated treatments for PTSD and SUD. Notably, in the
current study most patients dropped out before SWT
started (33%), or during the first phase of self-confrontation
of the SWT treatment (56%). Only one patient ended treat-
ment just after the self-confrontation phase (11%). This
suggests that patients were inclined to shudder from, or ter-
minate during, the assignments comprising trauma-focused
exposure. Future studies should explore whether a longer
phase of preparation for trauma-focused treatment may
increase the acceptability of this type of intervention.
The lack of significant between-group differences for
SUD in the current study is consistent with previous
findings in less severe patients [1,21,33] (Van Dam,
Vedel, Ehring, Emmelkamp: Integrated trauma-focused
treatment for concurrent posttraumatic stress disorder
and substance use disorder: a randomized controlled trial,
submitted). There may be several explanations for this
phenomenon (Van Dam, Vedel, Ehring, Emmelkamp:
Integrated trauma-focused treatment for concurrent
posttraumatic stress disorder and substance use dis-
order: a randomized controlled trial, submitted). First,
SUD treatment was equal in both conditions, which
may have been so effective that group differences were
leveled out. In addition, long-term follow-up may be
needed to prove differences between the two conditions
on SUD outcomes; PTSD improvements have a better
chance to positively influence SUD symptoms after a
longer period of time [21] (Van Dam, Vedel, Ehring,
Emmelkamp: Integrated trauma-focused treatment for
concurrent posttraumatic stress disorder and substance
use disorder: a randomized controlled trial, submitted).
A 1-year follow-up assessment is currently underway.
Besides the small sample size, a number of additional
limitations are noteworthy. First the current sample
comprised a mixed group of inpatients and day-care pa-
tients. However, the setting for inpatients and day-care
patients was very similar. For example, both groups
attended their treatment at the same location, the con-
tent of both programs was alike, and most important,
the group intervention for SUD was the same in both
conditions. Second, patients suffering from borderline
personality disorder were excluded from the study due
to ethical reasons. It is therefore not clear whether the
current results also apply to this subgroup of patients.
Third, whereas diagnoses of PTSD and SUD were
established using structured clinical interviews at pre-
and post-treatment, the 3 month follow-up assessment
exclusively comprised self-report measures, which can
be regarded as a limitation of the current study. A 1 year
follow-up assessment including structured clinical inter-
views to assess diagnostic criteria is currently underway
and will provide more conclusive evidence on the long-
term effects of the two treatment conditions.
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http://www.biomedcentral.com/1471-244X/13/172An important strength of this RCT is its specific focus
on external validity. The intervention was studied in a
routine clinical setting under everyday circumstances.
This means that results can easily be generalized to
regular clinical practice. Another strength was that all
patients were offered the same type of SUD treatment,
facilitating interpretations about the added value of
TAU + SWT compared to TAU.
Although the small sample size and the indirect nature
of findings, supporting a superiority of SWT + TAU, pre-
vent us from drawing firm conclusions, the outcomes of
this study are encouraging enough to continue investigat-
ing trauma-focused treatment for patients with concurrent
PTSD and SUD. Trauma-focused PTSD treatment
preliminary appears more effective in decreasing PTSD
and SUD symptoms than SUD treatment alone, without
jeopardizing patient’s safety or treatment retention
[33,34], also if it concerns a more severe SUD patient
group.Endnotes
aFisher’s excact test was calculated with integers.
bFisher’s excact test was calculated with integers.Competing interests
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